Ji Ru-Rong, Xu Zhen-Zhong, Gao Yong-Jing
Departments of Anesthesiology and Neurobiology, Duke University Medical Center, 595 LaSalle Street, Durham, North Carolina 27710, USA.
Pain Research Laboratory, Institute of Nautical Medicine, Jiangsu Key laboratory of Neuroregeneration, Nantong University, 19 Qixiu Road, Nantong 226001, Jiangsu 226001, China.
Nat Rev Drug Discov. 2014 Jul;13(7):533-48. doi: 10.1038/nrd4334. Epub 2014 Jun 20.
Current analgesics predominately modulate pain transduction and transmission in neurons and have limited success in controlling disease progression. Accumulating evidence suggests that neuroinflammation, which is characterized by infiltration of immune cells, activation of glial cells and production of inflammatory mediators in the peripheral and central nervous system, has an important role in the induction and maintenance of chronic pain. This Review focuses on emerging targets - such as chemokines, proteases and the WNT pathway - that promote spinal cord neuroinflammation and chronic pain. It also highlights the anti-inflammatory and pro-resolution lipid mediators that act on immune cells, glial cells and neurons to resolve neuroinflammation, synaptic plasticity and pain. Targeting excessive neuroinflammation could offer new therapeutic opportunities for chronic pain and related neurological and psychiatric disorders.
Nat Rev Drug Discov. 2014-7
Anesthesiology. 2018-8
Pharmacol Ther. 2020-8
Sci Am. 2014-12
Int J Mol Sci. 2021-5-14
Pharmacol Res. 2020-9
Joint Bone Spine. 2021-12
Nat Rev Rheumatol. 2025-8-26
Neurochem Res. 2025-8-23
Front Neurol. 2025-7-25
J Clin Invest. 2014-4-17
Nat Rev Immunol. 2014-2-28
J Clin Invest. 2014-2-17
CNS Neurol Disord Drug Targets. 2014
Prog Lipid Res. 2013-11-25
Nat Rev Neurosci. 2013-11-27